Haldol im to iv conversion

The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.

Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D 2 receptor antagonism and slow receptor dissociation kinetics. [42] It has effects similar to the phenothiazines . [17] The drug binds preferentially to D 2 and α 1 receptors at low dose (ED 50 = and  mg/kg, respectively), and 5-HT 2 receptors at a higher dose (ED 50 =  mg/kg). Given that antagonism of D 2 receptors is more beneficial on the positive symptoms of schizophrenia and antagonism of 5-HT 2 receptors on the negative symptoms, this characteristic underlies haloperidol's greater effect on delusions, hallucinations and other manifestations of psychosis. [43] Haloperidol's negligible affinity for histamine H 1 receptors and muscarinic M 1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms .

Preterm and term neonates:
Less than 32 weeks with tracheal intubation:
-Initial dose: mg/kg/hr ( mcg/kg/min) IV

Over 32 weeks with tracheal intubation:
-Initial dose: mg/kg/hr (1 mcg/kg/min) IV

Non-neonates and children:
Unpremedicated patients with tracheal intubation:
-Loading dose: to mg/kg IV once, administered over 2 to 3 minutes
-Initial dose: to mg/kg/hr (1 to 2 mcg/kg/min)

Premedicated patients with tracheal intubation:
-Initial dose: to mg/kg/hr (1 to 2 mcg/kg/min)

Hemodynamically compromised patients:
-Loading dose: The usual loading dosed should be increased in small increments.

-To establish therapeutic plasma levels in neonates, the infusion should be run more rapidly for the first several hours.
-Infusion rates should be reassessed to ensure that the lowest effective dose is used, especially after the first 24 hours.
-Extreme caution should be used in current/former preterm patients who do not have tracheal intubation.
-The rate of continuous infusion may be increased or decreased (., usually by 25% of the initial/subsequent rate) as necessary in premedicated non-neonates. Supplemental IV doses may be given to increase/maintain the desired effect.
-Patients should be monitored closely for hemodynamic instability, respiratory rate, and oxygen saturation, especially when this drug is used in those with hemodynamic instability.

Use: Sedation of intubated and mechanically ventilated patients during treatment in a critical care setting

Haldol im to iv conversion

haldol im to iv conversion


haldol im to iv conversionhaldol im to iv conversionhaldol im to iv conversionhaldol im to iv conversionhaldol im to iv conversion